Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALVO Alvotech	$11.14 -0.4%	$9.23	$7.35 ▼ $14.65	$3.36B	-0.02	138,257 shs	277,967 shs
APLS Apellis Pharmaceuticals	$17.41 +3.6%	$19.05	$16.10 ▼ $43.76	$2.19B	0.73	2.28 million shs	1.87 million shs
EXAI Exscientia	$4.84	$4.97	$3.80 ▼ $6.49	$632.93M	0.83	657,536 shs	N/A
SRRK Scholar Rock	$29.84 +3.4%	$30.47	$6.76 ▼ $46.98	$2.83B	0.37	1.27 million shs	839,647 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALVO Alvotech	-0.36%	+12.07%	+41.73%	-1.94%	-18.09%
APLS Apellis Pharmaceuticals	+3.63%	-2.08%	-4.39%	-30.78%	-57.65%
EXAI Exscientia	0.00%	0.00%	0.00%	0.00%	+3.64%
SRRK Scholar Rock	+3.40%	-2.04%	-8.94%	-23.13%	+224.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALVO Alvotech	2.415 of 5 stars	3.5	4.0	0.0	2.7	0.0	0.6
APLS Apellis Pharmaceuticals	4.441 of 5 stars	4.3	2.0	4.4	2.3	2.5	0.6
EXAI Exscientia	0.1636 of 5 stars	1.0	0.0	0.0	0.0	1.7	0.6
SRRK Scholar Rock	4.3771 of 5 stars	3.5	2.0	4.4	3.5	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALVO Alvotech	3.00	Buy	$18.00	61.58% Upside
APLS Apellis Pharmaceuticals	2.62	Moderate Buy	$39.89	129.15% Upside
EXAI Exscientia	2.00	Hold	$5.00	3.31% Upside
SRRK Scholar Rock	3.00	Buy	$42.67	42.98% Upside

Current Analyst Ratings Breakdown

Latest EXAI, ALVO, APLS, and SRRK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/22/2025	APLS Apellis Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$49.00 ➝ $41.00
5/14/2025	APLS Apellis Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$30.00 ➝ $20.00
5/14/2025	SRRK Scholar Rock	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$50.00
5/9/2025	APLS Apellis Pharmaceuticals	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Outperform	$75.00 ➝ $52.00
5/9/2025	APLS Apellis Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$41.00 ➝ $23.00
5/8/2025	APLS Apellis Pharmaceuticals	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform ➝ Sector Perform	$21.00 ➝ $18.00
5/8/2025	APLS Apellis Pharmaceuticals	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform ➝ Sector Perform	$28.00 ➝ $20.00
5/8/2025	APLS Apellis Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$30.00 ➝ $26.00
5/8/2025	APLS Apellis Pharmaceuticals	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$55.00 ➝ $47.00
5/7/2025	APLS Apellis Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$40.00 ➝ $29.00
4/29/2025	APLS Apellis Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$44.00

(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALVO Alvotech	$585.60M	5.74	N/A	N/A	N/A	∞
APLS Apellis Pharmaceuticals	$775.84M	2.82	N/A	N/A	$1.64 per share	10.62
EXAI Exscientia	$25.60M	24.72	N/A	N/A	$2.54 per share	1.91
SRRK Scholar Rock	$33.19M	85.36	N/A	N/A	$3.12 per share	9.56

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALVO Alvotech	-$551.73M	$0.37	N/A	55.70	N/A	-123.47%	N/A	-35.87%	N/A
APLS Apellis Pharmaceuticals	-$528.63M	-$1.79	N/A	N/A	N/A	-34.97%	-103.11%	-28.96%	8/7/2025 (Estimated)
EXAI Exscientia	-$181.56M	-$1.51	N/A	N/A	N/A	-882.09%	-49.10%	-33.13%	N/A
SRRK Scholar Rock	-$165.79M	-$2.53	N/A	N/A	N/A	N/A	-145.60%	-91.83%	8/14/2025 (Estimated)

Latest EXAI, ALVO, APLS, and SRRK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	SRRK Scholar Rock	-$0.63	-$0.67	-$0.04	-$0.67	N/A	N/A
5/7/2025	Q1 2025	ALVO Alvotech	-$0.17	$0.35	+$0.52	$0.35	N/A	N/A
5/7/2025	Q1 2025	APLS Apellis Pharmaceuticals	-$0.36	-$0.74	-$0.38	-$0.74	$197.61 million	$149.90 million
3/26/2025	Q4 2024	ALVO Alvotech	-$0.74	-$0.24	+$0.50	-$0.24	$97.99 million	$153.34 million
2/28/2025	Q4 2024	APLS Apellis Pharmaceuticals	-$0.37	-$0.29	+$0.08	-$0.29	$197.92 million	$212.50 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALVO Alvotech	N/A	N/A	N/A	N/A	N/A
APLS Apellis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
EXAI Exscientia	N/A	N/A	N/A	N/A	N/A
SRRK Scholar Rock	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALVO Alvotech	N/A	2.69	1.92
APLS Apellis Pharmaceuticals	1.91	4.36	3.73
EXAI Exscientia	0.06	4.54	4.54
SRRK Scholar Rock	0.63	3.88	3.88

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALVO Alvotech	N/A
APLS Apellis Pharmaceuticals	96.29%
EXAI Exscientia	41.58%
SRRK Scholar Rock	91.08%

Insider Ownership

Company	Insider Ownership
ALVO Alvotech	0.46%
APLS Apellis Pharmaceuticals	6.50%
EXAI Exscientia	16.40%
SRRK Scholar Rock	13.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALVO Alvotech	4	301.48 million	N/A	Not Optionable
APLS Apellis Pharmaceuticals	770	125.68 million	115.93 million	Optionable
EXAI Exscientia	280	130.77 million	109.32 million	Optionable
SRRK Scholar Rock	140	94.95 million	75.64 million	Optionable

EXAI, ALVO, APLS, and SRRK Headlines

Recent News About These Companies

Scholar Rock Holding Co. (NASDAQ:SRRK) Receives $42.67 Average Target Price from Brokerages

May 30 at 2:07 AM | americanbankingnews.com

Scholar Rock Holding Co. (NASDAQ:SRRK) Shares Sold by Polar Asset Management Partners Inc.

May 29 at 5:06 AM | marketbeat.com

Millennium Management LLC Sells 524,642 Shares of Scholar Rock Holding Co. (NASDAQ:SRRK)

May 29 at 3:38 AM | marketbeat.com

Scholar Rock to Present at the Jefferies Global Healthcare Conference

May 28 at 8:00 AM | businesswire.com

Nuveen Asset Management LLC Buys 122,638 Shares of Scholar Rock Holding Co. (NASDAQ:SRRK)

May 28 at 3:50 AM | marketbeat.com

Scholar Rock Holding Co. (NASDAQ:SRRK) Given Average Rating of "Buy" by Brokerages

May 28 at 1:31 AM | marketbeat.com

Scholar Rock Holding Co. (NASDAQ:SRRK) Shares Purchased by Voloridge Investment Management LLC

May 27 at 4:46 AM | marketbeat.com

Bank of America Corp DE Trims Stock Position in Scholar Rock Holding Co. (NASDAQ:SRRK)

May 27 at 3:15 AM | marketbeat.com

Two Sigma Advisers LP Sells 330,600 Shares of Scholar Rock Holding Co. (NASDAQ:SRRK)

May 25, 2025 | marketbeat.com

Two Sigma Investments LP Sells 221,365 Shares of Scholar Rock Holding Co. (NASDAQ:SRRK)

May 25, 2025 | marketbeat.com

Scholar Rock Holding Co. (NASDAQ:SRRK) Shares Acquired by ProShare Advisors LLC

May 25, 2025 | marketbeat.com

BNP Paribas Financial Markets Sells 13,394 Shares of Scholar Rock Holding Co. (NASDAQ:SRRK)

May 23, 2025 | marketbeat.com

Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. Purchases New Position in Scholar Rock Holding Co. (NASDAQ:SRRK)

May 22, 2025 | marketbeat.com

Scholar Rock Holding Co. (NASDAQ:SRRK) Shares Bought by Woodline Partners LP

May 22, 2025 | marketbeat.com

Soleus Capital Management L.P. Invests $7.24 Million in Scholar Rock Holding Co. (NASDAQ:SRRK)

May 21, 2025 | marketbeat.com

Rafferty Asset Management LLC Sells 37,595 Shares of Scholar Rock Holding Co. (NASDAQ:SRRK)

May 21, 2025 | marketbeat.com

Polar Asset Management Partners Inc. Trims Stock Holdings in Scholar Rock Holding Co. (NASDAQ:SRRK)

May 20, 2025 | marketbeat.com

Dimensional Fund Advisors LP Lowers Position in Scholar Rock Holding Co. (NASDAQ:SRRK)

May 20, 2025 | marketbeat.com

HC Wainwright Boosts Earnings Estimates for Scholar Rock

May 20, 2025 | marketbeat.com

Wedbush Forecasts Scholar Rock's Q2 Earnings (NASDAQ:SRRK)

May 20, 2025 | americanbankingnews.com

What is Wedbush's Estimate for Scholar Rock Q2 Earnings?

May 20, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

EXAI, ALVO, APLS, and SRRK Company Descriptions

Alvotech NASDAQ:ALVO

$11.14 -0.04 (-0.36%)

Closing price 05/29/2025 04:00 PM Eastern

Extended Trading

$11.23 +0.09 (+0.82%)

As of 05:01 AM Eastern

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.

Apellis Pharmaceuticals NASDAQ:APLS

$17.41 +0.61 (+3.63%)

Closing price 05/29/2025 04:00 PM Eastern

Extended Trading

$17.42 +0.00 (+0.03%)

As of 05/29/2025 07:56 PM Eastern

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

Exscientia NASDAQ:EXAI

Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy. It is also involved in the development of EXS4318, a PKC-theta inhibitor, under Phase 1 clinical trial for inflammation and immunology indications; EXS74539, a LSD1 inhibitor, under preclinical studies for SCLC, AML, and potential additional indications; EXS73565, a MALT1 inhibitor, under preclinical studies for multiple hematology indications; and DSP-0038, currently in Phase 1 studies. The company has collaboration agreements with Merck KGaA, Bristol Myers Squibb, Sanofi, Bill & Melinda Gates Foundation, Charité Universitätsmedizin Berlin, Rallybio, and GT Apeiron Therapeutics. Exscientia plc was founded in 2012 and is headquartered in Oxford, the United Kingdom.

Scholar Rock NASDAQ:SRRK

$29.84 +0.98 (+3.40%)

Closing price 05/29/2025 04:00 PM Eastern

Extended Trading

$29.84 0.00 (0.00%)

As of 05/29/2025 04:20 PM Eastern

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time